| NCT02855944 | III | Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy) | ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | Colorado, Georgia |
| Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT01851369 | II | Advanced solid tumors and granulosa cell ovarian cancer (in expansion) | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | View Drugs | Maryland |
| methoxyamine | TRC102 | Base excision repair inhibitor | | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent |
|
| NCT02576444 | II | Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations | A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors | View Drugs | Connecticut, Massachusetts, Ohio, Tennessee |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Capivasertib | Akt inhibitor AZD5363 | pan-AKT inhibitor | | Ceralasertib | AZD6738 | ATR kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT02571725 | II | Recurrent ovarian cancer with germline BRCA1/2 mutations (no prior anti-CTLA-4 mAb) | A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer | View Drugs | Florida, New Mexico, Ohio, Virginia |
| Olaparib | AZD2281, Lynparza | PARP inhibitor | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT02843165 | II | Advanced solid tumors with lesion treatable with radiotherapy | Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease | View Drugs | California |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03348631 | II | Recurrent or persistent endometrioid/clear cell ovarian cancer | A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma | View Drugs | Alaska, Arizona, Arkansas, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Virginia, Washington, Wisconsin, Wyoming |
| Tazemetostat | histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438 | EZH2 histone methyltransferase inhibitor |
|
| NCT02832167 | II | Advanced solid tumors | An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies | View Drugs | Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia |
| Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03428802 | II | Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | View Drugs | New Jersey |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03462342 | II | Recurrent ovarian cancer | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer | View Drugs | Pennsylvania |
| Ceralasertib | AZD6738 | ATR kinase inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT01876511 | II | Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | View Drugs | California, Maryland, New York, Ohio, Oregon, Pennsylvania |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03570619 | II | Advanced solid tumors with CDK12 alterations | IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations | View Drugs | Florida, Michigan, New York |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03579316 | II | Recurrent ovarian cancer (PD on or after prior PARP inhibitor) | A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Ovarian Cancer Patients Who Have Progressed During PARP Inhibition | View Drugs | Massachusetts, Texas |
| Adavosertib | WEE1 inhibitor AZD1775, MK1775, AZD1775 | WEE1 inhibitor | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT03610490 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | View Drugs | Texas |
| MDA-TIL | autologous tumor-infiltrating lymphocytes MDA-TIL | Anti-tumor immune response |
|
| NCT03651271 | II | Recurrent ovarian cancer with high MSI | An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer | View Drugs | California, Massachusetts, New York, Texas |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03693014 | II | Advanced solid tumors with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | View Drugs | New Jersey, New York |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | View Drugs | California, Minnesota |
| Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | View Drugs | Pennsylvania |
| Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | Rintatolimod | Atvogen, Ampligen | TLR-3 agonist and immune cell stimulator |
|
| NCT03673124 | II | Low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum | View Drugs | Oklahoma |
| Letrozole | Femara | Aromatase inhibitor | | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor |
|
| NCT03742895 | II | Advanced BRCA1/2-wild type solid tumors with DNA repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+ | A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | View Drugs | California, Georgia, Kentucky, Massachusetts, Michigan, Nebraska, New York, Oklahoma, Pennsylvania, South Dakota, Washington |
| Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT03836352 | II | Recurrent ovarian cancer (with tumor lesions < 5 cm) | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours. | View Drugs | New York, Texas |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03461952 | II | Advanced solid tumors with POLE and/or POLD1 mutations | A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay | View Drugs | New York |
| Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03697304 | II | Advanced solid tumors with prior PD-1/PD-L1 targeted treatment | An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy | View Drugs | California |
| BI 754091 | anti-PD-1 monoclonal antibody BI 754091 | Blocks PD-L1/2 inhibition of T cells | | BI 754111 | | Blocks LAG-3 inhibition of T cells |
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | View Drugs | Massachusetts |
|
| NCT02819843 | II | Advanced solid tumors - intratumoral injection | A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors | View Drugs | New Jersey, New York |
| Radiation Therapy | Radiotherapy, Irradiation | | | Talimogene Laherparepvec | GM-CSF-encoding oncolytic herpes simplex virus, T-VEC | Induces immune response and tumor cell lysis |
|
| NCT03909152 | II | Recurrent PR+ low grade serous or granulosa cell ovarian cancer | Basket Study of the Oral Progesterone Antagonist Onapristone ER (Apristor) in Women With Progesterone Receptor Positive (PR+) Recurrent Granulosa Cell Tumor, Low Grade Serous Ovarian Cancer or Endometrioid Endometrial Cancer | View Drugs | New Jersey, New York |
| Onapristone ER | extended-release onapristone | PR antagonist that blocks PR activation and the associated expression of PR-responsive genes |
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | View Drugs | Kentucky |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT02710253 | II | Advanced solid tumors with progression on systemic immunotherapy | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | View Drugs | Texas |
| Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03616834 | II | Advanced solid tumors with high MSI on checkpoint inhibitor treatment without evidence of complete or partial response | Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone | View Drugs | Arizona, California, Georgia, Idaho, Indiana, Maryland, Michigan, Ohio, Oregon, South Carolina, South Dakota, Texas, Virginia, Wisconsin |
| Tomivosertib | eFT508 | MNK1/2 inhibitor |
|
| NCT03449108 | II | Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | View Drugs | Texas |
| Aldesleukin | | IL-2 receptor agonist | | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | LN-145 | autologous tumor infiltrating lymphocytes LN-145, autologous TILs LN-145 | Anti-tumor immune response |
|
| NCT03704467 | Ib/II | Platinum sensitive ovarian cancer with disease progression following maintenance treatment with a PARP inhibitor (at least 2 prior platinum therapies) | A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | View Drugs | Alabama, Alaska, Arkansas, California, Connecticut, Georgia, Maine, Massachusetts, Michigan, New Jersey, New York, Oklahoma, Rhode Island, Texas |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | Berzosertib | VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 | ATR kinase inhibitor | | Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT03717415 | Ib/II | Advanced solid tumors | An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors | View Drugs | California, Texas |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Rebastinib | multitargeted tyrosine kinase inhibitor DCC-2036 | Multi-targeted kinase inhibitor |
|
| NCT03330405 | Ib/II | Platinum sensitive recurrent ovarian cancer | A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors | View Drugs | Arkansas, California, District of Columbia, Massachusetts, Michigan, Minnesota, New York, Ohio, Pennsylvania, Texas |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor |
|
| NCT02606305 | Ib/II | Advanced FRalpha+ ovarian cancer | A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer | View Drugs | Alabama, California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Mirvetuximab Soravtansine | M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate | ADC: anti-FOLR1 + microtubule destabilizer (DM4) |
|
| NCT02785250 | Ib/II | Recurrent ovarian cancer | A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer | View Drugs | California, Georgia, New York, Oregon, Pennsylvania, Texas |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | DPX-Survivac | survivin antigen vaccine DPX-Survivac | Immune response against cancer expressing survivin |
|
| NCT02994953 | Ib | Advanced solid tumors | A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors | View Drugs | California, Connecticut, Florida, Louisiana, Minnesota, Missouri, Ohio, Oklahoma, Oregon, South Carolina, Texas, Vermont, Washington |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | NHS-IL12 | M9241, immunocytokine NHS-IL12 | IL-12 receptor agonist |
|
| NCT03206177 | Ib | Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma | Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary | View Drugs | Oklahoma |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Galunisertib | LY2157299 | TGFBR1 antagonist | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT03307785 | Ib | Advanced solid tumors | Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer | View Drugs | Arizona, California, Florida, Michigan, New Mexico, Ohio, Oklahoma, South Carolina, Tennessee, Texas |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Niraparib | MK4827, Zejula | PARP inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | TSR-022 | | Blocks TIM-3 inhibition of T cells | | TSR-042 | anti-PD-1 monoclonal antibody TSR-042, ANB011, Dostarlimab | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03318445 | Ib | Advanced solid tumors with BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, or RAD54L mutations (inc expansion) | Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | View Drugs | California |
| Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT03695380 | Ib | Platinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion) | A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer | View Drugs | Arizona, California, Florida, Georgia, Maryland, Missouri, New York, Oklahoma, Tennessee, Wisconsin |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Cobimetinib | Cotellic, GDC-0973, XL518 | MEK1 inhibitor | | Niraparib | MK4827, Zejula | PARP inhibitor |
|
| NCT03586661 | Ib | Recurrent ovarian cancer with BRCA1/2 mutations (or high grade serous with BRCA1/2-wild type)(inc expansion) | A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | View Drugs | Texas |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | | Niraparib | MK4827, Zejula | PARP inhibitor |
|
| NCT03589651 | Ib | Advanced solid tumors (inc expansion) | A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors | View Drugs | California, Connecticut, Florida, Illinois, New Jersey, New York, North Carolina, Pennsylvania, Texas, Washington |
| Epacadostat | 3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360 | Inhibits IDO1 to stimulate immune response | | INCB050465 | PI3K-delta inhibitor INCB050465 | PI3K delta inhibitor | | MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells |
|
| NCT03872947 | Ib | Platinum sensitive or partially sensitive ovarian cancer | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | View Drugs | New Jersey, Wisconsin |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism |
|
| NCT03514121 | Ia/Ib | Advanced solid tumors (in ovarian expansion) | A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors | View Drugs | Arizona, California, Connecticut, Illinois, Michigan, Oklahoma, Tennessee, Texas, Utah, Washington |
| FPA150 | anti-B7-H4 monoclonal antibody FPA150 | blocks B7-H4 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03209401 | Ia/Ib | Advanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion) | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies | View Drugs | District of Columbia |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Niraparib | MK4827, Zejula | PARP inhibitor |
|
| NCT02913313 | I/IIa | Advanced solid tumors | Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | New Jersey, New York, Pennsylvania, Utah |
| BMS-986207 | anti-TIGIT monoclonal antibody BMS-986207 | Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02953457 | I/II | Recurrent, persistent or refractory high grade serous ovarian cancer with BRCA1/2 or HRD or MMR gene alterations or high LOH/HRD scores | A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation | View Drugs | New York |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | Olaparib | AZD2281, Lynparza | PARP inhibitor | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT02484404 | I/II | Recurrent ovarian cancer | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | View Drugs | Maryland |
| Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT02487095 | I/II | Extrapulmonary small cell ovarian cancer | A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers | View Drugs | Maryland |
| Berzosertib | VX-970, M6620, VE-822, ATR kinase inhibitor VX-970 | ATR kinase inhibitor | | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor |
|
| NCT02734004 | I/II | Platinum sensitive recurrent ovarian cancer | A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors | View Drugs | Georgia, Maryland, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, Wisconsin |
| Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | Olaparib | AZD2281, Lynparza | PARP inhibitor |
|
| NCT02432378 | I/II | Platinum sensitive ovarian cancer with first recurrence in peritoneal cavity - intranodal injection (inc expansion) | A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines | View Drugs | Pennsylvania |
| Alpha-DC1 vaccine | | Anti-tumor immune response | | Celecoxib | Celebrex | | | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent |
|
| NCT03251924 | I/II | Advanced solid tumors | A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | View Drugs | Massachusetts, New Jersey, Pennsylvania, Tennessee |
| BMS-986226 | anti-ICOS BMS-986226, anti-inducible T-cell co-stimulator BMS-986226 | Stimulates ICOS to increase T cell activity and immune response | | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03446040 | I/II | Advanced solid tumors | A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | View Drugs | California, Colorado, Pennsylvania, Tennessee |
| BMS-986258 | anti-TIM3 antibody BMS-986258 | Blocks TIM-3 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03729596 | I/II | Advanced solid tumors | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors | View Drugs | Michigan, North Carolina, Virginia |
| MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells | | MGC018 | A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payload | ADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin) |
|
| NCT03157128 | I/II | Advanced solid tumors | A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | View Drugs | Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nevada, New York, North Carolina, Ohio, Oregon, Pennsylvania, Tennessee, Texas, Utah, Virginia, Wisconsin |
| LOXO-292 | RET kinase inhibitor LOXO-292 | RET-kinase inhibitor |
|
| NCT03665285 | I/II | Advanced solid tumors | A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | View Drugs | California, Connecticut, New Jersey, New York, Texas |
| NC318 | anti-S15 monoclonal antibody NC318, anti-Siglec-15 monoclonal antibody NC318 | Blocks tumor-associated macrophage stimulation of tumor growth |
|
| NCT03369223 | I/II | Advanced solid tumors | A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors | View Drugs | Colorado, Florida, Maryland, New Jersey, New York, Ohio, Oregon, Pennsylvania, South Carolina, Texas, Virginia, Washington |
| BMS-986249 | Probody of ipilumumab | Blocks CTLA-4 inhibition of T cells | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03761914 | I/II | Recurrent or persistent WT1+ ovarian cancer | A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers | View Drugs | California, Florida |
| Galinpepimut-S | | Immune response against cancer expressing WT1 | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03775850 | I/II | Advanced MSI-high solid tumors that relapsed following PD-1/L-1 checkpoint inhibitor therapy | A Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | View Drugs | Florida, Oklahoma, Tennessee |
| EDP1503 | monoclonal microbial EDP1503 | | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03744468 | I/II | Advanced solid tumors | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | View Drugs | Colorado, Pennsylvania |
| BGB-A425 | | Blocks TIM-3 inhibition of T cells | | Tislelizumab | anti-PD-1 monoclonal antibody BGB-A317 | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02660034 | I/Ib | Platinum sensitive recurrent ovarian cancer (at least 2 prior platinum therapies) | A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors | View Drugs | Arizona, California, Colorado, Florida, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Virginia |
| Pamiparib | PARP inhibitor BGB-290 | PARP inhibitor | | Tislelizumab | anti-PD-1 monoclonal antibody BGB-A317 | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03061188 | I/Ib | Advanced solid tumors (inc expansion--ATR, ATM, CHEK1/2, BRCA1/2, BAP1, BARD1, FANCA/C/D2/E, RAD50/51, PALB2, CDK12, POLE, POLD1, PRKDC, ERCC2, POLQ, MRE11A, NBN mutations or FANCA/C/D2/E or EMSY amplification) | Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes | View Drugs | Illinois |
| Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Veliparib | ABT-888 | PARP inhibitor |
|
| NCT03054298 | I | Recurrent or persistent mesothelin+ serous ovarian cancer | Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers | View Drugs | Pennsylvania |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Hu-CART-meso cells | | Immune response against cancer expressing mesothelin |
|
| NCT03154281 | I | Advanced ovarian cancer (no prior PARPi) | A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer | View Drugs | South Dakota |
| Everolimus | Zortress, RAD001, Certican, Afinitor | mTOR inhibitor | | Niraparib | MK4827, Zejula | PARP inhibitor |
|
| NCT02628574 | I | Advanced solid tumors (in expansion) | A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors | View Drugs | Illinois, New Mexico, Ohio, Pennsylvania, Tennessee |
| Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells | | TRX518 | anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518 | GITR (glucocorticoid-induced TNFR) agonist |
|
| NCT01239134 | I | Advanced solid tumors (in expansion) | Part A: A First-in-Human Single Ascending Dose Study of TRX518 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies Part B: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part C: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose | View Drugs | New York |
| TRX518 | anti-huGITR monoclonal antibody TRX518, anti-huGITR mAb TRX518, anti-huGITR MoAb TRX518 | GITR (glucocorticoid-induced TNFR) agonist |
|
| NCT01376505 | I | Advanced solid tumors (in ovarian expansion) | Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors | View Drugs | Ohio |
| MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine | | Immune response against cancer expressing HER2 |
|
| NCT03056833 | I | Platinum sensitive recurrent ovarian cancer | Phase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | View Drugs | Pennsylvania |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor |
|
| NCT03289962 | I | Advanced solid tumors | A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors | View Drugs | Arizona, California, Colorado, Connecticut, District of Columbia, Massachusetts, Nevada, New York, Oklahoma, Oregon, Pennsylvania, Tennessee, Washington |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | RO7198457 | personalized cancer vaccine RO7198457, PCV RO7198457 | Immune response against tumor-associated antigens |
|
| NCT03213964 | I | Recurrent advanced ovarian cancer only in abdomen/pelvis | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | View Drugs | Minnesota |
| NK100 | NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100 | Anti-tumor immune response |
|
| NCT03310541 | I | Advanced solid tumors with AKT1, AKT2, or AKT3 mutations | A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3 | View Drugs | New Jersey, New York |
| Capivasertib | Akt inhibitor AZD5363 | pan-AKT inhibitor |
|
| NCT02715284 | I | Advanced solid tumors (inc expansion) | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors | View Drugs | Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maine, Massachusetts, Michigan, Minnesota, Missouri, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin |
| TSR-042 | anti-PD-1 monoclonal antibody TSR-042, ANB011, Dostarlimab | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03313778 | I | Advanced solid tumors with high MSI or high TMB (in expansion) | A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors | View Drugs | Florida, Massachusetts, New Jersey, New York, North Carolina, Tennessee |
| mRNA-4157 | mRNA-based personalized cancer vaccine mRNA-4157 | Anti-tumor immune response | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT01434316 | I | Advanced solid tumors including those with BRCA1/2 mutations (in expansion) | Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors | View Drugs | Massachusetts |
| Dinaciclib | SCH 727965, CDK inhibitor SCH 727965 | CDK1, 2, 5, 9 inhibitor | | Veliparib | ABT-888 | PARP inhibitor |
|
| NCT02433626 | I | Recurrent ovarian cancer | A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies | View Drugs | Texas |
| Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | | COTI-2 | mutant p53 activator COTI-2 | Mutant p53 activator |
|
| NCT02534922 | I | Recurrent or persistent ovarian cancer | Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | View Drugs | South Carolina |
| Prolanta | | Prolactin receptor antagonist |
|
| NCT03017131 | I | Recurrent or refractory ovarian cancer | A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer | View Drugs | New York |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Decitabine | 5-aza-dCyd, deoxyazacytidine, dezocitidine, Dacogen | DNA methylation inhibitor | | Genetically Engineered NY-ESO-1-specific T Lymphocytes | | Immune response against cancer expressing NY-ESO-1 |
|
| NCT03030378 | I | Advanced solid tumors | A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors | View Drugs | California, Colorado, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Missouri, New Jersey, North Carolina, Ohio, Pennsylvania, Virginia |
| IL-12 | cytotoxic lymphocyte maturation factor interleukin-12, Ro 24-7472, recombinant interleukin-12, natural killer cell stimulatory factor NM-IL-12 | IL-12 receptor agonist | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT02498912 | I | MUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies) | A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors | View Drugs | New York |
| 4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes | 4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes | Immune response against cancer expressing CA125 | | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor |
|
| NCT03435250 | I | Advanced solid tumors with CDKN2A deletion (inc expansion) | A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP | View Drugs | Connecticut, Massachusetts, New York, Tennessee |
| AG-270 | | methionine adenosyltransferase 2a (MAT2A) inhibitor |
|
| NCT03538028 | I | Advanced solid tumors (inc expansion) | A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies | View Drugs | California, New Jersey, North Carolina, Tennessee |
| INCAGN02385 | | Blocks LAG-3 inhibition of T cells |
|
| NCT03134638 | I | Advanced solid tumors (in ovarian expansion) | A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors | View Drugs | Alabama, Arizona, California, Illinois, Massachusetts, New York, Oklahoma, Rhode Island, Tennessee, Texas |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | SY-1365 | SY 1365, CDK7 inhibitor SY-1365 | CDK7 inihibitor |
|
| NCT03517956 | I | Advanced solid tumors with FGFR over-expression | A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors | View Drugs | California, Illinois, Maryland, Massachusetts, Michigan, Nevada, New York, South Carolina, Texas |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | | Rogaratinib | pan-FGFR tyrosine kinase inhibitor BAY1163877, BAY1163877 | pan-FGFR kinase inhibitor |
|
| NCT03255070 | I | Advanced HER+ solid tumors | A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression | View Drugs | Missouri |
| ARX788 | anti-HER2 antibody-drug conjugate ARX788, ADC ARX788 | ADC: anti-HER2 + microtubule destabilizer (MMAF) |
|
| NCT03330561 | I | Advanced HER2+ solid tumors (inc expansion) | A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors | View Drugs | Arizona, California, District of Columbia, Maryland, New York, Pennsylvania, Tennessee, Texas |
| PRS-343 | anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343 | Immune response against cancer expressing HER2 |
|
| NCT03585764 | I | Recurrent or persistent FRalpha+ high grade serous ovarian cancer | Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | View Drugs | Pennsylvania |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | MOv19-BBz CAR T | | Immune response against cancer expressing folate receptor |
|
| NCT03486301 | I | Advanced solid tumors (inc expansion) | Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | View Drugs | Florida, Tennessee, Texas |
| BDB001 | | TLR agonist and immune cell stimulator | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03144661 | I | Recurrent advanced serous ovarian cancer | A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | View Drugs | Alabama, New York |
| INCB062079 | | FGFR4 inhibitor |
|
| NCT03059823 | I | Advanced solid tumors (inc expansion) | A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors | View Drugs | Arizona, Michigan, New Jersey, North Carolina, Texas, Virginia |
| MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells |
|
| NCT03431948 | I | Advanced solid tumors (amenable to radiation treatment) | Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors | View Drugs | Illinois |
| Cabiralizumab | anti-CSF1R monoclonal antibody FPA008, FPA008 | CSF1R antagonist and tumor-associated macrophage inhibitor | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Radiation Therapy | Radiotherapy, Irradiation | | | Urelumab | BMS-663513, anti-CD137 monoclonal antibody, anti-4-1BB monoclonal antibody | Stimulates 4-1BB (CD137) to increase T cells and immune response |
|
| NCT03691376 | I | Recurrent or refractory NY-ESO-1+ ovarian cancer | A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer | View Drugs | New York |
| Aldesleukin | | IL-2 receptor agonist | | Melphalan | Sarcolysin, Alkeran, Alkerana, Melfalan, Phenylalanine mustard | DNA damaging agent | | NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) | | Immune response against cancer expressing NY-ESO-1 | | NY-ESO-1 CD8-TCR Engineered T Cells | | Immune response against cancer expressing NY-ESO-1 |
|
| NCT03502733 | I | Advanced solid tumors | Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas | View Drugs | Maryland, Texas |
| Copanlisib | BAY 80-6946, MEK inhibitor BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03318900 | I | Recurrent high grade ovarian cancer | Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer | View Drugs | Texas |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | IL-21-Primed CD8+ Tumor Antigen-Specific T Cells | adoptively transferred central memory-type CTL targeting ovarian cancer antigens | Immune response against cancer expressing PRAME and/or COL6A3 | | Utomilumab | PF-05082566 | Stimulates 4-1BB (CD137) to increase T cells and immune response |
|
| NCT03724890 | I | Advanced solid tumors | A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors | View Drugs | California, Florida, Illinois, New York, Ohio, Oklahoma, Tennessee |
| Avelumab | Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio | Blocks PD-L1 inhibition of T cells | | M3814 | DNA-PK inhibitor MSC2490484A | DNA-PK inhibitor | | Radiation Therapy | Radiotherapy, Irradiation | |
|
| NCT03725436 | I | Advanced solid tumors that are TP53 WT | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer | View Drugs | Texas |
| ALRN-6924 | MDM2/MDMX inhibitor ALRN-6924 | MDM2 and MDMX inhibitor | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor |
|
| NCT03719326 | I | Advanced ovarian cancer (inc expansion) | A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast and Gynecologic Malignancies | View Drugs | Arizona, Colorado, Florida, Maryland, Nevada, North Carolina, Oregon, Texas, Virginia, Washington |
| AB928 | AB928, a dual antagonist of the A2aR and A2bR adenosine receptors | Blocks adenosine A2A/B receptors inhibition of T cells | | IPI-549 | PI3K-gamma inhibitor IPI-549 | PI3K gamma inhibitor | | Liposomal doxorubicin | Doxil, Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride | Topoisomerase II inhibitor |
|
| NCT03139370 | I | Advanced MAGE-A3/A6+, HLA-DPB1*04:01+ (inc expansion) | A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers | View Drugs | California, Florida, Massachusetts, New York, Texas |
| Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | KITE-718 | MAGEA3/A6-targeted TCR-transduced T cells KITE-718, autologous MAGE-A3/A6-specific TCR gene-engineered lymphocytes KITE-718 | immune response against cancer expressing MAGE-A3/A6 |
|
| NCT03739931 | I | Advanced solid tumors (inc expansion) - intratumoral injection | A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade | View Drugs | Colorado, Connecticut, Florida, Michigan, Tennessee |
| Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | | mRNA-2752 | lipid nanoparticle-encapsulated OX40L, IL23, IL36gamma mRNA-2752 | | | Tremelimumab | anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Blocks CTLA-4 inhibition of T cells |
|
| NCT03875287 | I | Advanced solid tumors | A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors | View Drugs | Maryland |
| ASTX727 | CDA inhibitor E7727/decitabine combination agent ASTX727 | DNA methylation inhibitor |
|
| NCT03821935 | I | Advanced solid tumors | A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors | View Drugs | Connecticut, North Carolina, Texas |
| ABBV-151 | ARGX-115 | binds GARP in complex with inactive TGF-beta preventing release of active TGF-beta | | ABBV-181 | anti-PD1 monoclonal antibody ABBV-181 | Blocks PD-L1 inhibition of T cells |
|
| NCT03831295 | I | Advanced solid tumors | Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014] | View Drugs | California |
| BMS-986178 | anti-OX40 antibody BMS 986178 | Stimulates OX40 to increase T cell activation and immune response | | SD-101 | TLR9 agonist SD-101, ISS-ODN SD-101 | TLR9 agonist and immune cell activator |
|
| NCT03840200 | I | Recurrent ovarian cancer | A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer | View Drugs | Pennsylvania |
| Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor |
|
| NCT03841110 | I | Advanced solid tumors (inc expansion) | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1) | View Drugs | California, Minnesota, Texas |
| Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | | Cyclophosphamide | Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | FT500 | | Anti-tumor immune response | | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03556228 | I | Advanced solid tumors (inc expansion) | An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma | View Drugs | California |
| VMD-928 | TrkA inhibitor VMD-928 | TRK kinase inhibitor |
|
| NCT03968406 | I | Recurrent ovarian cancer - without ascites | Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers | View Drugs | Texas |
| Radiation Therapy | Radiotherapy, Irradiation | | | Talazoparib | Talazoparib Tosylate, BMN-673, MDV3800 | PARP inhibitor |
|
| NCT03219268 | I | Advanced solid tumors (inc expansion) | A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms | View Drugs | Arizona, California, Florida, Illinois, Maryland, Massachusetts, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas |
| Margetuximab | anti-HER2/c-erbB2 monoclonal antibody, anti-HER2 mAb MGAH22 | HER2 antagonist | | MGD013 | anti-PD-1/anti-LAG-3 DART protein MGD013, dual-affinity retargeting protein MGD013 | Blocks LAG-3 and PD-1 inhibition of T cells |
|
| NCT03416335 | I | Advanced solid tumors (inc expansion) | A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, in Adult Patients With Advanced Solid Tumors | View Drugs | Indiana, Texas |
| DSP-0509 | toll-like receptor 7 agonist DSP-0509 | TLR7 agonist and immune cell activator |
|
| NCT03628677 | I | Advanced solid tumors (inc expansion) | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | View Drugs | North Carolina, Texas, Washington |
| AB122 | | Blocks PD-L1 inhibition of T cells | | AB154 | | Blocks T cell binding to CD112 and CD155 to enable activation of CD226 signaling in NK and CD8 T cells |
|
| NCT03920839 | I | Advanced solid tumors at first recurrence | A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | View Drugs | California |
| Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | | MGA012 | anti-PD-1 monoclonal antibody MGA012, INCMGA00012 | Blocks PD-L1 inhibition of T cells | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Pemetrexed | Pemetrexed disodium, Alimta | DHFR and Thymidylate synthase inhibitor |
|
| NCT03240861 | I | Advanced NY-ESO-1+ solid tumors | Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies | View Drugs | California |
| Aldesleukin | | IL-2 receptor agonist | | Busulfan | Busulfex, busulphan, CB-2041, Glyzophrol, GT-41, joacamine, leucosulfan, mielucin, misulban, misulfan, mitosan, myeleukon, myeloleukon, myelosan, mylecytan, myleran, sulfabutin, WR-19508 | DNA damaging agent | | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | | NY-ESO-1 TCR transgenic T cells and NY-ESO-1 TCR/sr39TK transgenic stem cells | | Immune response against cancer expressing NY-ESO-1 |
|
| NCT03444714 | I | Advanced solid tumors with lesion amenable to palliative radiotherapy - intratumoral injection | Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors | View Drugs | Illinois |
| Radiation Therapy | Radiotherapy, Irradiation | | | RiMO-301 | metal-organic framework (MOF) compound RiMO-301, MOF compound RiMO-301 | following intratumoral injection and radiation induces ROS-mediated DNA damage |
|
| NCT03156114 | I | Advanced solid tumors with high MSI or high TMB and prior checkpoint inhibitor treatment (in expansion) | An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors | View Drugs | Florida, Oklahoma, Tennessee, Wisconsin |
| BI 754091 | anti-PD-1 monoclonal antibody BI 754091 | Blocks PD-L1/2 inhibition of T cells | | BI 754111 | | Blocks LAG-3 inhibition of T cells |
|
| NCT02990481 | I | Advanced solid tumors (in expansion) | A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously in Patients With Advanced Solid Tumors | View Drugs | Arizona |
| TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism |
|
| NCT03894540 | I | Advanced solid tumors (inc expansion) | A Phase I, Open Label, Dose Escalation and Dose Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumour Activity of IPN60090 as Single Agent and in Combination in Patients With Advanced Solid Tumours | View Drugs | Texas |
| IPN60090 | | Undisclosed mechanism | | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | | Pembrolizumab | MK3475, SCH 900475, Lambrolizumab, Keytruda | Blocks PD-L1/2 inhibition of T cells |
|
| NCT03893955 | I | Advanced solid tumors | A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors | View Drugs | Alabama, California, Connecticut, North Carolina, Texas, Virginia |
| ABBV-368 | | Stimulates OX40 to increase T cell activation and immune response | | ABBV-927 | anti-CD40 agonist monoclonal antibody ABBV-927 | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response |
|
